LexaGene Holdings Inc. (LXXGF)
- GlobeNewswire
LexaGene Announces MiQLab® System Sale to Veterinary Hospital in California
BEVERLY, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, is pleased to announce that it has entered into a purchase agreement with a veterinary hospital in southern California. Dr. Jack Regan, LexaGene’s CEO and Founder stated, “We are pleased to close our first sale following Dr. Jane Sykes’ webinar o
- GlobeNewswire
LexaGene Verifies CDC Monkeypox Assay Works on MiQLab System and Readies Company Should an EUA be Declared
BEVERLY, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, announces the System can perform the Centers for Disease Control and Prevention (CDC) Monkeypox real-time PCR test.1 On July 23rd, the World Health Organization declared Monkeypox a public health emergency of international concern,2 and on August
- GlobeNewswire
LexaGene’s MiQLab System Generates Leptospira Results in as Soon as 30 minutes using Isothermal Chemistry
BEVERLY, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic syndromic testing for veterinarians, announces it has successfully configured the MiQLab System to use isothermal chemistry for individual pathogen detection in as soon as 30 minutes, which complements our traditional real-time PCR chemistry for syndromic
